venglustat GZ402671

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company, Sanofi

Conditions

Congenital Cystic Kidney DiseaseSandhoff DiseaseTay-Sachs Disease

Phase 3

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

TerminatedNCT04221451

Genzyme, a Sanofi CompanySandhoff Disease, Tay-Sachs Disease

Start: 2020-06-29End: 2024-12-26Updated: 2026-01-28

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

TerminatedNCT04705051

SanofiCongenital Cystic Kidney Disease

Start: 2021-02-09End: 2021-07-13Updated: 2025-09-17

Related Papers

Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers.

2023-06-031 citations

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Journal of Parkinson s Disease2021-12-1059 citations

GM1 Gangliosidosis-A Mini-Review.

2021-09-0364 citations